Could blood pressure drugs slow Parkinson's? major trial launches

NCT ID NCT07207057

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large Phase 3 trial is testing whether two common drugs, telmisartan and terazosin, can slow the progression of Parkinson's disease. 1,200 participants will receive either a drug or a placebo for up to 36 months. The study uses a flexible design that can add new treatments over time, aiming to find effective therapies faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telmisartan and terazosin (drugs repurposed for Parkinson's disease)
What this could lead to: If successful, this could provide new, safe treatments that slow the progression of Parkinson's disease, helping people maintain their abilities longer.
What could go wrong: This is an early-stage platform trial; the drugs may not slow progression. Side effects from the medications are possible, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSONS DISEASE (PD)

Contacts and locations

Locations

Clinical Ageing Research Unit
RECRUITING

Newcastle, NE4 5PL, United Kingdom
UCLH
RECRUITING

London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.